Ultragenyx Pharmaceutical Inc. (RARE) Stock Price

RAREStock

$14.54−57.20%52W

Market Cap$1.43B

P/E—

PEG Ratio—

Div yield—

Beta0.35

RARE Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-50.73%

Price vs S&P 500 (4W)0.57%

VGM Score48.28

Book Value / Share (Quarterly)$0.10

P/TBV (Annual)50.46x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)22.81%

Cash Flow / Share (Quarterly)$-5.01

Price vs S&P 500 (YTD)-48.71%

Gross Margin (TTM)83.11%

Net Profit Margin (TTM)-81.73%

EPS (TTM)$-5.84

10-Day Avg Trading Volume3.85M

EPS Excl Extra (TTM)$-5.84

Revenue Growth (5Y)19.95%

EPS (Annual)$-5.83

ROI (Annual)-50.60%

Gross Margin (Annual)83.80%

Net Profit Margin (5Y Avg)-130.13%

Cash / Share (Quarterly)$2.96

Revenue Growth QoQ (YoY)28.53%

ROA (Last FY)-37.53%

Revenue Growth TTM (YoY)17.50%

EBITD / Share (TTM)$-4.92

ROE (5Y Avg)-141.85%

Operating Margin (TTM)-73.67%

Cash Flow / Share (Annual)$-5.04

P/B Ratio156.51x

P/B Ratio (Quarterly)316.50x

Net Income / Employee (Annual)$-419,400

EV / Revenue (TTM)3.42x

Net Interest Coverage (TTM)-14.43x

ROA (TTM)-44.37%

EPS Incl Extra (Annual)$-5.83

Current Ratio (Annual)2.48x

Quick Ratio (Quarterly)1.43x

3-Month Avg Trading Volume3.71M

52-Week Price Return-57.20%

Revenue / Employee (TTM)$522,900

Tangible BV / Share (Quarterly)$0.83

P/S Ratio (Annual)2.13x

Asset Turnover (Annual)0.44x

52-Week High$39.89

Operating Margin (5Y Avg)-118.69%

EPS Excl Extra (Annual)$-5.83

CapEx CAGR (5Y)-13.72%

Tangible BV CAGR (5Y)-31.88%

26-Week Price Return-40.82%

Quick Ratio (Annual)2.22x

13-Week Price Return-50.34%

Total Debt / Equity (Annual)3.41x

Current Ratio (Quarterly)1.73x

Enterprise Value$2.45B

Revenue / Share Growth (5Y)8.90%

Asset Turnover (TTM)0.54x

Book Value / Share Growth (5Y)-24.58%

Revenue / Employee (Annual)$490,900

Inventory Turnover (Annual)2.25x

Pretax Margin (Annual)-84.84%

Cash / Share (Annual)$7.04

3-Month Return Std Dev99.74%

Gross Margin (5Y Avg)89.47%

Net Income / Employee (TTM)$-427,400

ROE (Last FY)-222.95%

Net Interest Coverage (Annual)-10.08x

EPS Basic Excl Extra (Annual)$-5.83

Receivables Turnover (TTM)4.42x

Total Debt / Equity (Quarterly)90.54x

EPS Incl Extra (TTM)$-5.84

Receivables Turnover (Annual)4.81x

ROI (TTM)-58.61%

P/S Ratio (TTM)2.00x

Pretax Margin (5Y Avg)-129.67%

Revenue / Share (Annual)$6.83

Tangible BV / Share (Annual)$0.83

Price vs S&P 500 (52W)-72.73%

Year-to-Date Return-36.78%

5-Day Price Return-4.97%

EPS Normalized (Annual)$-5.83

ROA (5Y Avg)-38.33%

Net Profit Margin (Annual)-85.44%

Month-to-Date Return-3.26%

Cash Flow / Share (TTM)$-8.66

EBITD / Share (Annual)$-5.34

Operating Margin (Annual)-79.49%

LT Debt / Equity (Annual)3.21x

ROI (5Y Avg)-73.69%

LT Debt / Equity (Quarterly)83.39x

EPS Basic Excl Extra (TTM)$-5.84

P/TBV (Quarterly)50.46x

P/B Ratio (Annual)15.22x

Inventory Turnover (TTM)2.30x

Pretax Margin (TTM)-81.21%

Book Value / Share (Annual)$2.76

Price vs S&P 500 (13W)-53.03%

Beta0.35x

Revenue / Share (TTM)$7.04

ROE (TTM)-414.17%

52-Week Low$12.73

vGradeC

gGradeB

mGradeD

vgmGradeC

RARE Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 4, 2026	-$1.00	-$0.90	+9.74%(+$0.10)
Q1 2026	May 5, 2026	-$1.46	-$1.54	-5.73%(-$0.08)
Q4 2025	Feb 12, 2026	-$1.17	-$1.29	-10.10%(-$0.12)
Q3 2025	Nov 4, 2025	-$1.21	-$1.81	-49.69%(-$0.60)
Q2 2025	Aug 5, 2025	-$1.32	-$1.17	+11.42%(+$0.15)

RARE Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.20

4.23

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
RAREUltragenyx Pharmaceutical Inc.	C	B	D	2.0x	17.5%	83.1%	—	$14.54
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical is a biopharmaceutical company specializing in treatments for rare and ultra-rare genetic diseases. The company's marketed portfolio includes Crysvita (for X-linked hypophosphatemia) and Mepsevii (for Mucopolysaccharidosis VII), with additional therapies in development. Operating globally across North America, Europe, Asia-Pacific, and other regions, Ultragenyx generates the majority of its revenue from North America.

RARE Next Earnings Report

Report dateNov 3, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.75

Revenue estimate$183.49M

Also reporting on Nov 3, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

RARE Insider Transactions

SellSep 15, 2026
HUIZENGA THEODORE ALAN
Officer
Shares: 1,283Value: $17,410
SellSep 3, 2026
HUIZENGA THEODORE ALAN
Officer
Shares: 161Value: $2,252
SellAug 3, 2026
HORN HOWARD
Chief Financial Officer
Shares: 4,696Value: $117,024
SellAug 3, 2026
PARSCHAUER KARAH HERDMAN
Officer
Shares: 1,900Value: $47,348

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

NTLAIntellia Therapeutics, IncIn Vitro Diagnostics
MAZEMaze Therapeutics, Inc. Common StockBiological Products
IMCRImmunocore Holdings plc American Depositary SharesBiological Products
HUNHuntsman CorporationChemicals
SCLStepan Co.Soap & Detergents
COAGHemab Therapeutics Holdings, Inc. Common StockBiological Products
REXREX American Resources Corp.Industrial Chemicals
UANCVR Partners, LPAgricultural Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.2

Strong Buy

Consensus rating

52-Week Range

Low$12.73

High$39.89